DocGo Valuation

Is DCGO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • PM vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DCGO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DCGO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DCGO's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for DCGO?

Other financial metrics that can be useful for relative valuation.

DCGO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.6x
Enterprise Value/EBITDA15.6x
PEG Ratio0.7x

Price to Earnings Ratio vs Peers

How does DCGO's PE Ratio compare to its peers?

The above table shows the PE ratio for DCGO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29x
CCRN Cross Country Healthcare
8.1x-21.2%US$584.8m
VMD Viemed Healthcare
36.2x49.4%US$332.9m
PNTG Pennant Group
40.7x25.6%US$509.0m
NRC National Research
31.3xn/aUS$968.3m
DCGO DocGo
46.8x70.3%US$343.9m

Price-To-Earnings vs Peers: DCGO is expensive based on its Price-To-Earnings Ratio (46.8x) compared to the peer average (29x).


Price to Earnings Ratio vs Industry

How does DCGO's PE Ratio compare vs other companies in the US Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a12.2%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a12.2%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: DCGO is expensive based on its Price-To-Earnings Ratio (46.8x) compared to the US Healthcare industry average (24.1x).


Price to Earnings Ratio vs Fair Ratio

What is DCGO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DCGO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio46.8x
Fair PE Ratio67.3x

PM vs Fair Ratio: DCGO is good value based on its Price-To-Earnings Ratio (46.8x) compared to the estimated Fair Price-To-Earnings Ratio (67.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DCGO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.31
US$12.14
+266.8%
10.3%US$14.00US$10.00n/a7
Feb ’25US$3.60
US$12.14
+237.3%
10.3%US$14.00US$10.00n/a7
Jan ’25US$5.59
US$12.72
+127.5%
14.4%US$16.00US$10.00n/a7
Dec ’24US$6.01
US$12.72
+111.6%
14.4%US$16.00US$10.00n/a7
Nov ’24US$6.09
US$13.29
+118.2%
9.6%US$16.00US$12.00n/a7
Oct ’24US$5.33
US$13.29
+149.3%
9.6%US$16.00US$12.00n/a7
Sep ’24US$8.74
US$13.57
+55.3%
10.3%US$16.00US$12.00n/a7
Aug ’24US$8.49
US$13.17
+55.1%
8.1%US$15.00US$12.00n/a6
Jul ’24US$9.37
US$13.17
+40.5%
8.1%US$15.00US$12.00n/a6
Jun ’24US$9.16
US$12.83
+40.1%
10.5%US$15.00US$11.00n/a6
May ’24US$8.22
US$12.83
+56.1%
10.5%US$15.00US$11.00n/a6
Apr ’24US$8.65
US$13.20
+52.6%
8.8%US$15.00US$12.00n/a5
Mar ’24US$9.39
US$13.20
+40.6%
10.1%US$15.00US$11.00n/a5
Feb ’24US$9.99
US$13.00
+30.1%
10.9%US$15.00US$11.00US$3.605
Jan ’24US$7.07
US$12.60
+78.2%
12.9%US$15.00US$11.00US$5.595
Dec ’23US$7.22
US$12.60
+74.5%
12.9%US$15.00US$11.00US$6.015
Nov ’23US$10.20
US$12.83
+25.8%
12.3%US$15.00US$11.00US$6.096
Oct ’23US$9.92
US$12.83
+29.4%
12.3%US$15.00US$11.00US$5.336
Sep ’23US$9.99
US$12.83
+28.5%
12.3%US$15.00US$11.00US$8.746
Aug ’23US$7.97
US$12.67
+58.9%
14.2%US$15.00US$10.00US$8.496
Jul ’23US$7.26
US$12.67
+74.5%
14.2%US$15.00US$10.00US$9.376
Jun ’23US$7.48
US$12.67
+69.3%
14.2%US$15.00US$10.00US$9.166
May ’23US$7.02
US$14.00
+99.4%
17.5%US$19.00US$11.00US$8.226
Apr ’23US$8.69
US$14.80
+70.3%
14.4%US$19.00US$13.00US$8.655
Mar ’23US$6.92
US$15.40
+122.5%
21.6%US$22.00US$13.00US$9.395
Feb ’23US$7.53
US$15.40
+104.5%
21.6%US$22.00US$13.00US$9.995

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.